2017 ACVIM Forum Research Abstract Program

xygenase-2 (COX-2), transforming growth factor (TGF)-b, indoleamine-2,3-dioxygenase (IDO) and hepatocyte growth factor, increased in the presence of RAW264.7 cells. Expression of proinflammatory TNF-a, interferon-c and IL-6 decreased, and expression of anti-inflammatory IL-10 increased during coculture of mitogen-stimulated allogeneic fPBMCs with fAT-MSCs. TGF-b, COX-2 and IDO expression and prostaglandin E-2 production from fAT-MSCs increased in the presence of allogeneic fPBMCs. Our data suggested that soluble factors secreted from fAT-MSCs play an important role in the immunomodulatory effects of these cells. These findings may be helpful in the application of fAT-MSCs to feline patients with immune-related diseases. Gene therapy is an emerging treatment modality in human medicine and animal models including dogs and cats are often used in preclinical studies to demonstrate efficacy and safety. Research into gene therapies for some conditions in animals has started as well. Adeno-associated virus (AAV) based vectors are among the most common delivery mechanisms. It is well established that antibodies to AAV vectors can impact the success of gene transfer. The primary objective of this study was to determine if pet populations have circulating antibodies to two AAV vectors used for gene therapy.